You are here
Media Advisory
Thursday, October 31, 2024
三亿体育官网 trial of rectal microbicide for HIV prevention begins in the United States
Study will assess safety and acceptability of rectal douche for pre-exposure prophylaxis.
What
A clinical trial sponsored by the National Institutes of Health (三亿体育官网) has launched to examine the safety and acceptability of a novel rectal HIV microbicide douche containing the antiretroviral drug tenofovir. This 鈥渙n-demand鈥 HIV prevention approach involves using the microbicide prior to a potential exposure from receptive anal intercourse.
Several forms of HIV pre-exposure prophylaxis (PrEP) are in use in the United States and globally, namely daily oral pills, long-acting injections, and a monthly vaginal ring. The Centers for Disease Control and Prevention advises that gay, bisexual and other men who have sex with men who meet certain criteria can take around the time of sex to prevent HIV acquisition, but there is insufficient evidence to support its use in other populations. Rectal microbicides are another HIV prevention method being explored for use in an 鈥渙n-demand鈥 manner to expand the choices available to eligible people who engage in receptive anal intercourse and who stand to benefit from using PrEP. 聽聽聽
The clinical trial will enroll about 150 adults assigned male at birth who have regular experience using an unmedicated rectal douche before receptive anal intercourse. Participants will each receive 鈥渙n-demand鈥 tenofovir rectal microbicide douche during one two-month period and on-demand oral PrEP with tenofovir disoproxil fumarate and emtricitabine in another two-month period. All participants will be monitored closely for safety. The study also will assess participants鈥 experience using their assigned PrEP method, including measures of acceptability, adherence, and method preference. The study will take place at eight sites in the United States.
While , 67% of U.S. HIV diagnoses from 2018-2022 were among gay, bisexual, and other men who have sex with men, pointing to the need for expanded HIV prevention options. The mid-stage study is sponsored 三亿体育官网鈥檚 National Institute of Allergy and Infectious Diseases (NIAID) and implemented through the 三亿体育官网-funded HIV Prevention Trials Network (HPTN). 三亿体育官网 remains committed to developing safe and effective HIV prevention methods that people need, want, and are able to use.
More information about this study, also known as HPTN 106, is available at ClinicalTrials.gov under identifier .
Who
Sheryl Zwerski, D.N.P., director of the Prevention Sciences Program in NIAID鈥檚 Division of AIDS, is available to discuss this research.
NIAID conducts and supports research鈥攁t 三亿体育官网, throughout the United States, and worldwide鈥攖o study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the .
About the National Institutes of Health (三亿体育官网): 三亿体育官网, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. 三亿体育官网 is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about 三亿体育官网 and its programs, visit www.nih.gov.
三亿体育官网…Turning Discovery Into Health庐